CATALOGO DEI PRODOTTI DELLA RICERCA

BONIFACIO, Massimiliano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.815
EU - Europa 4.504
AS - Asia 2.683
AF - Africa 33
SA - Sud America 28
OC - Oceania 26
Continente sconosciuto - Info sul continente non disponibili 6
Totale 12.095
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.789
CN - Cina 1.692
GB - Regno Unito 1.406
SG - Singapore 641
RU - Federazione Russa 499
IT - Italia 493
SE - Svezia 469
FR - Francia 406
IE - Irlanda 404
DE - Germania 337
FI - Finlandia 230
UA - Ucraina 90
HK - Hong Kong 65
VN - Vietnam 65
IN - India 50
NL - Olanda 43
BE - Belgio 37
ID - Indonesia 29
KR - Corea 27
AU - Australia 25
JP - Giappone 24
TR - Turchia 23
TG - Togo 22
IR - Iran 20
CA - Canada 19
RO - Romania 14
AT - Austria 10
AR - Argentina 8
BR - Brasile 8
CH - Svizzera 8
CL - Cile 8
CZ - Repubblica Ceca 8
ES - Italia 8
GR - Grecia 7
PL - Polonia 7
NO - Norvegia 6
MA - Marocco 5
NP - Nepal 5
DK - Danimarca 4
EU - Europa 4
MX - Messico 4
BD - Bangladesh 3
DZ - Algeria 3
LK - Sri Lanka 3
LT - Lituania 3
LV - Lettonia 3
MY - Malesia 3
PE - Perù 3
TH - Thailandia 3
UZ - Uzbekistan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
AZ - Azerbaigian 2
CR - Costa Rica 2
GE - Georgia 2
HU - Ungheria 2
IL - Israele 2
IQ - Iraq 2
KG - Kirghizistan 2
KH - Cambogia 2
KZ - Kazakistan 2
PH - Filippine 2
PK - Pakistan 2
PT - Portogallo 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
TW - Taiwan 2
AE - Emirati Arabi Uniti 1
BY - Bielorussia 1
CY - Cipro 1
EE - Estonia 1
HR - Croazia 1
LA - Repubblica Popolare Democratica del Laos 1
MK - Macedonia 1
MU - Mauritius 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PA - Panama 1
SI - Slovenia 1
SM - San Marino 1
UG - Uganda 1
VE - Venezuela 1
Totale 12.095
Salva come PNG Salva come JPEG
Città #
Southend 1.303
Chandler 968
Singapore 527
Woodbridge 505
Dublin 402
Beijing 401
Ann Arbor 329
Jacksonville 266
Houston 255
Ashburn 248
Wilmington 194
Lawrence 172
Princeton 172
Verona 144
Jinan 131
Nanjing 121
New York 120
Shenyang 120
Redmond 88
Sindelfingen 78
Hebei 76
Hong Kong 64
Helsinki 59
Tianjin 53
Zhengzhou 48
Falls Church 46
Nanchang 44
Ningbo 44
Taizhou 44
Changsha 43
Fuzhou 43
Redwood City 43
Dong Ket 40
Bologna 38
Brussels 37
Haikou 37
Santa Clara 37
Hangzhou 36
Guangzhou 34
Milan 34
Norwalk 30
Jakarta 28
Seattle 28
Kent 27
Jiaxing 26
Los Angeles 26
Seoul 25
Taiyuan 24
Lomé 22
Chicago 21
Groningen 21
Tokyo 19
Dearborn 16
Provo 16
Rome 16
Düsseldorf 15
Boardman 14
Dallas 14
Lanzhou 13
Chengdu 12
Washington 12
Lancaster 11
San Francisco 11
Kochi 10
Perth 10
Brescia 8
Fremont 8
Shanghai 8
Timisoara 8
Vienna 8
Amsterdam 7
Fairfield 7
Leawood 7
Moscow 7
Riva 7
Ardabil 6
Clearwater 6
Costa Mesa 6
Munich 6
Nürnberg 6
Vancouver 6
Athens 5
Buffalo 5
Florence 5
Palermo 5
Parsa 5
San Jose 5
Tehran 5
Toronto 5
Andover 4
Augusta 4
Bergamo 4
Cambridge 4
Colombo 4
Hefei 4
Hyderabad 4
Melbourne 4
Mountain View 4
Newark 4
Newbury Park 4
Totale 8.106
Salva come PNG Salva come JPEG
Nome #
Epidemiology of mastocytosis in adults based on a multidisciplinary diagnostic approach. 225
Notch singalling inhibition as a multi-target therapy to overcome bone marrow microenvironment-mediated drug resistance in AML 138
Notch signalling drives bone marrow stromal cell-mediated chemoresistance in acute myeloid leukemia 136
Role of GSK-3 signalling in non-promyelocitic acute myeloid leukemia (AML) cell response to chemotherapy 130
CAL2 Monoclonal Antibody Is a Rapid and Sensitive Assay for the Detection of Calreticulin Mutations in Essential Thrombocythemia and May Provide Prognostic Informations 128
BCR-ABL fusion transcript b2a2 is associated with a higher risk of non-optimal early response in CP-CML patients treated with standard dose imatinib: a study from Gruppo Triveneto LMC. 125
BLAST: A Confirmatory, Single-Arm, Phase 2 Study of Blinatumomab, a Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Patients with Minimal Residual Disease B-Precursor Acute Lymphoblastic Leukemia (ALL) 124
Value of flow cytometry in the diagnosis of indolent systemic mastocytosis. 122
Clonal mast cell disorders limited to bone marrow: not a negligible disease. 121
α-bisabolol is an effective proapoptotic agent against BCR-ABL+ cells in synergism with Imatinib and Nilotinib 120
Predictors for response to ruxolitinib in real-life: an observational independent study on 266 patients with myelofibrosis 119
Longitudinal Evaluation of Bone Mineral Density and Bone Metabolism Markers in Patients with Indolent Systemic Mastocytosis Without Osteoporosis 118
Inhibition of GSK-3 Signalling Enhances Sensitivity of Non-Promyelocitic Acute Myeloid Leukemia (AML) Cell to Chemotherapy 116
A study of the crosstalk between CD30 and CXCR4 115
Predictors for Response to Ruxolitinib in Real-Life: An Observational Independent Study on 408 Patients with Myelofibrosis 114
Autoimmune complications are frequent in splenic and nodal marginal zone lymphomas 113
Role of Wnt/β-Catenin Signalling in Acute Myeloid Leukemia (AML) Cell Response to Chemotherapy 113
CXCL12 and [N33A]CXCL12 in 5637 and HeLa Cells: Regulating HER1 Phosphorylation via Calmodulin/Calcineurin 111
TP53 mutations in adult acute lymphoblastic leukemia (ALL) are relatively frequent in molecularly negative case of both B- and T-lineage and correlate with poor response to induction therapy 110
Inhibition of Notch signalling overcomes bone marrow stromal-mediated anti-apoptotic and chemoresistance effects in AML. 110
Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis 109
The impact of a 7-day prednisone (PDN) pretreatment in adult (less than 60y) acute lymphoblastic leukemia (ALL) therapy: results of LAL2000 vs LAL0496. 109
CAL2 monoclonal antibody is a rapid and sensitive assay for the detection of calreticulin mutations in essential thrombocythemia and may provide prognostic informations 109
Rational of targeting WNT/beta-catenin signaling in acute myeloid leukemia (AML) 109
Pro-apoptotic activity of α-bisabolol in preclinical models of primary human acute leukemia cells 107
Predictors of stable deep molecular response in chronic phase chronic myeloid leukemia patients treated with dasatinib or nilotinib after imatinib failure 107
The Sesquiterpene Oil {alpha}-Bisabolol Induces Apoptosis of B-Chronic Lymphocytic Leukemia Primary Cells 104
ALK-positive anaplastic large cell lymphoma with PAX-5 expression: report of a case 103
Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories 103
Somatic D816V KIT mutation in a case of adult-onset familial mastocytosis. 100
Absence of TCL1A expression is a useful diagnostic feature in splenic marginal zone lymphoma. 97
Isolated bone marrow mastocytosis: an underestimated subvariant of indolent systemic mastocytosis 95
Hyperchidam Verona897 Regimen Is Effective in Treatment of Advanced Peripheral T Cell Lymphoma (PTCL): The GITIL Experience in 33 Cases 95
A preliminary experience with the HyperCHiDAM Verona intensive chemotherapy regimen in heavily pretreated refractory Hodgkin's lymphoma 94
Sesquiterpene α-bisabolol, which binds to Bid in lipid rafts, induces apoptosis in BCR/ABL+ cell lines through membrane depolarization. 92
Systemic mastocytosis: a muldisciplinary approach (Review) [Lamastocitosi sistemica: Un approccio multidiscliplinare] 92
High levels of tumor load reduction after intensive chemotherapy favorably affect the prognosis of BCR/ABL+ ALL adult patients receiving Imatinib Mesylate alone as a post-consolidation treatment according to the Italian GIMEMA LAL 0201/A protocol 92
A simple score predicts clonal mast cell disorders in patients with systemic reactions to Hymenoptera venom without skin lesions 92
Unexpected subacute leucoencephalopathy following intrathecal methotrexate and cytarabine administration in a patient homozygous for MTHFR 677C→T polymorphism. 91
Short-term, intensive chemotherapy regimen is equally effective in Burkitt lymphoma (BL) and in the novel WHO 2008 entity “B-cell lymphoma intermediate between DLBCL and BL". 91
Predictive factors of stable deep molecular response in chronic myeloid leukemia patients treated with imatinib standard dose: a study from the Gruppo Triveneto LMC. 90
Clonal mast cell disorders in patients with severe Hymenoptera venom allergy and normal serum tryptase levels 89
Back to life – Living, treating, managing myelofibrosis: the burden of illness for patients and their families 88
The impact of sensitive KIT D816V detection on recognition of Indolent Systemic Mastocytosis 88
Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response 88
CAL2 monoclonal antibody is a rapid and sensitive assay for the detection of calreticulin mutations in essential thrombocythemia patients 88
A Survey on Clinical and Biological Characteristic and Therapy Management of an Italian Series of 455 Adult Patients with Systemic Mastocytosis on Behalf of Italian Registry of Mastocytosis 87
CD66b-CD64dimCD115- cells in the human bone marrow represent neutrophil-committed progenitors 87
Improved detection of the C-KIT D816V mutation using allele-specific arms real time PCR assay allows a finer recognition of patients with indolent systemic mastocytosis. 86
Plasmacytoid dendritic cell leukemia: a rapidly evolving disease presenting with skin lesions sensitive to radiotherapy plus hyperthermia. 85
BCR-ABL mutations in chronic myeloid leukemia (CML) patients (pts) with failure and warning to first- and second-lline tyrosine kinase inhibitor (TKI) therapy: what is the advantage of Next-Generation Sequencing (NGS) over conventional sequencing? 85
Serum tryptase levels differently change over time in indolent systemic mastocytosis with or without skin lesions. 84
Therapeutic targeting of Lyn kinase to treat chorea-acanthocytosis 84
Mitochondrial-Mediated Apoptosis by the Sesquiterpene Oil {alpha}-Bisabolol and Its Synergism with Imatinib and Nilotinib In BCR-ABL+ Cells. 83
In Chronic Myeloid Leukemia Patients on 2nd-Line Tyrosine Kinase Inhibitor Therapy, Deep Sequencing at the Time of Warning May Allow Sensitive Detection of Emerging BCR-ABL1 Mutants 83
High incidence of autoimmune complications in 82 patients with non-MALT marginal zone lymphomas. 83
Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy 83
Real-life comparison of dasatinib and nilotinib as second-line therapy after imatinib failure for chronic phase CML 83
Anaphylactic Reactions After Discontinuation of Hymenoptera Venom Immunotherapy: A Clonal Mast Cell Disorder Should Be Suspected 83
Molecular “warning” CML patients: a retrospective study of Gruppo Triveneto LMC. 82
Inhibition of Notch signaling enhances chemosensitivity in B cell precursor acute lymphoblastic leukemia 81
Regulative Loop between β-catenin and Protein Tyrosine Receptor Type γ in Chronic Myeloid Leukemia 81
Ultra-deep sequencing (UDS) allows more sensitive detection of the D816V and other KIT gene mutations in systemic mastocytosis 80
Comparison of dasatinib and nilotinib as second-line therapy after imatinib failure in chronic phase chronic myeloid leukemia patients. 80
Skeletal implications of isolated bone marrow mastocytosis (reply): Indolent systemic mastocytosis without skin involvement vs. isolated bone marrow mastocytosis (reply) 79
The Plant-Derived Agent {alpha}-Bisabolol Induces Apoptosis of Leukemic Blasts Ex Vivo. 79
Blastic plasmacytoid dendritic cell leukemia: preliminary results of a retrospective italian multicentric study. 78
Dickkopf-1 and sclerostin serum levels in patients with systemic mastocytosis 78
Multiple large osteolytic lesions in a patient with systemic mastocytosis: a challenging diagnosis 78
PBX/E2A transcript positive B-lymphoblastic leukemia (B-ALL) presenting with bilateral renal and myocardial involvement: a case report. 77
Bone Disease in Mastocytosis 77
Characterization of a new B-ALL cell line with constitutional defect of the Notch signaling pathway 76
EUTOS Score Identifies Cases with Poor Outcome in Patients with Early Chronic Phase Chronic Myeloid Leukemia, Though Not Predictive for Optimal Response to Imatinib 75
Ultra-Deep Sequencing (UDS) Allows More Sensitive Detection of the D816V and Other Kit Gene Mutations in Systemic Mastocytosis 75
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms 75
Regulative loop between beta-catenin and protein tyrosine phosphatase receptor type gamma (PTPRG) in chronic myeloid leukemia 75
Notch Signaling Molecules as Prognostic Biomarkers for Acute Myeloid Leukemia 74
Small Molecule Inhibitors of Microenvironmental Wnt/β-Catenin Signaling Enhance the Chemosensitivity of Acute Myeloid Leukemia 71
The serological prevalence of SARS-CoV-2 infection in patients with chronic myeloid leukemia is similar to that in the general population 71
TCL1A expression in marginal zone lymphoma: a clinico-pathological evaluation in paired spleen and bone marrow samples 70
Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients 70
How patients perceive a switch from imatinib to nilotinib: results of a patient-centered analysis 69
Macrophages may promote cancer growth via a GM-CSF/HB-EGF paracrine loop that is enhanced by CXCL12. 69
Modified HyperCVAD and rituximab for the treatment of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. 67
Hymenoptera Anaphylaxis and C-kit Mutations: An Unexpected Association 65
Efficacy and Safety of Ruxolitinib in Elderly Patients (> 75 years) with Myelofibrosis 65
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis 65
Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements 65
Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients 64
EUTOS Score Predicts Optimal Response To Imatinib According To The Revised ELN Recommendations Better Than Sokal Score: A Study From The “Gruppo Triveneto LMC” 63
Intensive short-term chemotherapy regimen induces high remission rate (over 90%) and event-free survival both in children and adult patients with advanced sporadic Burkitt lymphoma/leukemia 63
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 62
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation 62
International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study 62
EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukaemia 61
Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk CML patients with favourable response to imatinib front-line. 61
Mast Cell Disorders In Drug Hypersensitivity 61
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study 61
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study 61
Combination of EUTOS score and 3-months BCR-ABL transcript level identifies a distinct subgroup of ECP-CML patients with high risk of non optimal response and imatinib discontinuation. 59
Totale 9.013
Salva come PNG Salva come JPEG
Categoria #
all - tutte 48.166
article - articoli 31.231
book - libri 0
conference - conferenze 16.656
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 279
Totale 96.332
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020956 0 0 0 0 95 143 95 47 89 188 152 147
2020/20211.232 121 218 63 134 218 108 22 22 50 20 162 94
2021/20221.381 106 374 36 141 109 56 24 73 72 40 78 272
2022/20232.692 190 264 263 470 208 704 33 152 297 24 46 41
2023/20241.591 73 128 90 158 175 197 63 109 27 86 379 106
2024/20251.485 187 240 214 700 144 0 0 0 0 0 0 0
Totale 12.386